These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17631602)

  • 1. New challenges in kidney cancer therapy: bevacizumab.
    Ravaud A
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix89. PubMed ID: 17631602
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
    Roncone D; Satoskar A; Nadasdy T; Monk JP; Rovin BH
    Nat Clin Pract Nephrol; 2007 May; 3(5):287-93. PubMed ID: 17457362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.
    Bono P; Elfving H; Utriainen T; Osterlund P; Saarto T; Alanko T; Joensuu H
    Ann Oncol; 2009 Feb; 20(2):393-4. PubMed ID: 19211503
    [No Abstract]   [Full Text] [Related]  

  • 6. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab in renal-cell cancer.
    Sonpavde G
    N Engl J Med; 2003 Oct; 349(17):1674. PubMed ID: 14573745
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bevacizumab and arterial hypertension or proteinuria: management].
    Senellart H; Bennouna J
    Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP; Blackwell KL
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy in patients with metastatic renal cell carcinoma.
    Escudier BJ
    Clin Adv Hematol Oncol; 2010 Oct; 8(10):665-6. PubMed ID: 21317861
    [No Abstract]   [Full Text] [Related]  

  • 11. Technology evaluation: bevacizumab, Genentech/Roche.
    Salgaller ML
    Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overstated conclusions of a pooled analysis of bevacizumab in colon cancer.
    Goffin JR; Talavera JR
    J Clin Oncol; 2006 Jan; 24(3):528-9; author reply 529-30. PubMed ID: 16421433
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
    McDermott DF; George DJ
    Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab (Avastin).
    Med Lett Drugs Ther; 2004 Jun; 46(1184):47-8. PubMed ID: 15212050
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
    Wilkes GM
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
    [No Abstract]   [Full Text] [Related]  

  • 18. Using bevacizumab to treat metastatic cancer: UK consensus guidelines.
    Miles D; Bridgewater J; Ellis P; Harrison M; Nathan P; Nicolson M; Raouf S; Wheatley D; Plummer C
    Br J Hosp Med (Lond); 2010 Dec; 71(12):670-7. PubMed ID: 21135762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapeutic opportunities in metastatic renal cell carcinoma].
    Buess M
    Praxis (Bern 1994); 2009 Apr; 98(9):481-6. PubMed ID: 19404907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B
    J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.